Entheon Biomedical Corp (ENBI.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 11/30
| 11-2020 | 03-2020 | 03-2019 | 03-2018 | 03-2017 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 3 | N/A | N/A | N/A | N/A |
| Income taxes - deferred | N/A | 0 | -73 | -39 | 0 |
| Accounts receivable | -66 | 11 | -11 | N/A | N/A |
| Other Working Capital | -1,198 | 8 | -72 | 63 | 0 |
| Other Operating Activity | -1,576 | -121 | -66 | -92 | -2 |
| Operating Cash Flow | $-2,838 | $-102 | $-221 | $-67 | $-2 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -85 | -411 | -163 | 0 |
| Net Acquisitions | 1,154 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -248 | N/A | N/A | N/A | N/A |
| Sale Of Investment | 185 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $1,082 | $-85 | $-411 | $-163 | $0 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 0 | 25 | 0 |
| Debt Repayment | -3 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 4,433 | 0 | 1,673 | 592 | 0 |
| Other Financing Activity | 0 | 95 | -160 | -59 | 0 |
| Financing Cash Flow | $4,430 | $95 | $1,513 | $557 | $0 |
| Beginning Cash Position | 113 | 1,224 | 344 | 18 | 20 |
| End Cash Position | 2,787 | 1,132 | 1,224 | 344 | 18 |
| Net Cash Flow | $2,674 | $-92 | $880 | $326 | $-2 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,838 | -102 | -221 | -67 | -2 |
| Capital Expenditure | -9 | -85 | -411 | -163 | N/A |
| Free Cash Flow | -2,847 | -187 | -633 | -231 | -2 |